New developments in the treatment of low high-density lipoprotein cholesterol

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Pharmacology

Background:

• Reduced levels of high-density lipoprotein (HDL) cholesterol are a significant risk factor for coronary artery disease (CAD) development and progression.
• Clinical outcome studies have confirmed the benefits of statin therapy in reducing cardiovascular events, even in patients with normal cholesterol levels.
• Subgroup analyses indicate that patients with low HDL cholesterol particularly benefit from statin therapy.

Purpose of the Study:

• To review the use of various HDL-raising agents in managing arteriographic progression.
• To explore the potential mechanisms of action of these HDL-raising agents.
• To highlight the importance of HDL-raising agents in treating high-risk patients with low HDL.

Main Methods:

• Review of clinical outcome studies involving statin therapy.
• Analysis of recent outcome trials on fibrate therapy.
• Examination of studies on HDL-raising agents, both singly and in combination.
• Discussion of potential mechanisms of action for HDL-raising therapies.

Main Results:

• Statin therapy has been verified to reduce the risk of initial or recurrent cardiovascular events.
• Subgroup analyses show that patients with low HDL cholesterol benefit from statin therapy.
• Recent fibrate therapy trials suggest a potential role for these medications in subjects with low HDL.

Conclusions:

• HDL-raising agents, including statins and fibrates, play a role in managing cardiovascular risk, especially in patients with low HDL levels.
• The mechanisms of action of these agents are crucial considerations for treating high-risk patients.
• Further research into HDL-raising therapies may offer improved strategies for cardiovascular disease prevention.